Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ945 in Amyotrophic Lateral Sclerosis
NCT04066244Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of sotuletinib in amyotrophic lateral sclerosis (ALS), sponsored by Novartis. Started Dec 2019; status: terminated.
02
Drugs
sotuletinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04066244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066244.